[Abuja, Nigeria, September 2, 2025]– Numelec Africa Holdings (NAH) and Digistain, a UK-based oncology diagnostics company, have announced a landmark partnership to introduce the Digistain novel risk profiling test for hormone receptor-positive breast cancer patients in Nigeria.
This collaboration aims to democratise access to life-saving cancer technologies and transform breast cancer care in Africa.
The Digistain test stratifies patients as low-risk or high-risk of recurrence, providing oncologists with a powerful decision-making tool to determine whether chemotherapy is required.
The test has published data showing 99% accuracy at 5 years and 95% accuracy at 10 years, making it a reliable and effective tool for breast cancer diagnosis.
The partnership aims to significantly reduce patient costs, cut diagnostic turnaround times, and streamline physician workflows.
El-Rufai paid bandits with taxpayers’ funds, says Gov Sani’s aide
Dr. Ese Owie, Executive Chairman of Numelec Africa Holdings, said: “This partnership has the potential to redefine cancer care in Nigeria, giving physicians and patients alike the clarity and confidence to make life-saving treatment decisions.”
Dr. Hemmel Amrania, CEO & Founder of Digistain stated: “By harnessing our patented, AI-enabled diagnostic platform, we can empower Nigerian oncologists with rapid, accurate, and affordable risk stratification, ensuring that breast cancer patients receive the most appropriate treatment without unnecessary exposure to chemotherapy.”
*About the Companies:*
● Numelec Africa Holdings: A pioneering force in social infrastructure optimization, with operations across 38 African countries, focusing on delivering innovative, cost-effective, and impactful solutions.
● Digistain: A patented, MHRA-approved software-as-a-medical-device developed at Imperial College London, providing rapid, reagent-free prognostic risk stratification for hormone receptor-positive breast cancer.
Media Contact:
Lai Oluwasegun, Group Head, Operations & Administration, Numelec Africa Holdings
Email: admin@numelecafrica.com | Tel: +234 909 433 7227
Stay ahead with the latest updates! Join The ConclaveNG on WhatsApp and Telegram for real-time news alerts, breaking stories, and exclusive content delivered straight to your phone. Don’t miss a headline — subscribe now!
 and Digistain, a UK-based oncology diagnostics company, have announced a landmark partnership to introduce the Digistain novel risk profiling test for hormone receptor-positive breast cancer patients in Nigeria.){kind=link}